Corbus Pharmaceuticals Holdings (CRBP) Notes Payables (2013 - 2024)

Corbus Pharmaceuticals Holdings has reported Notes Payables for 12 years, with the latest figure at $77000.0 in Q2 2024.

• On a quarterly basis, Notes Payables rose 50.52% year-over-year to $77000.0 in Q2 2024; TTM through Jun 2024 was $77000.0, a 50.52% increase from a year earlier, with the FY2023 full-year figure at $301000.0, down 14.81% from the prior year.
• Notes Payables was $77000.0 for Q2 2024 at Corbus Pharmaceuticals Holdings, down from $189818.0 in the prior quarter.
• The five-year high for Notes Payables was $803000.0 in Q1 2021, with the low at $36868.0 in Q3 2023.
• Average Notes Payables over 5 years is $350738.6, with a median of $252129.0 recorded in 2023.
• The largest YoY upside for Notes Payables was 449.86% in 2021 against a maximum downside of 83.24% in 2021.
• Over 5 years, Notes Payables stood at $797000.0 in 2020, then dropped by 3.65% to $767938.0 in 2021, then slumped by 53.99% to $353323.0 in 2022, then dropped by 14.81% to $301000.0 in 2023, then slumped by 74.42% to $77000.0 in 2024.
• The last three Notes Payables figures came in at $77000.0 (Q2 2024), $189818.0 (Q1 2024), and $301000.0 (Q4 2023), per Business Quant data.